A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 18 May 2018
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 May 2018 Planned End Date changed from 30 Nov 2019 to 30 Jun 2019.
- 07 May 2018 Planned primary completion date changed from 30 May 2019 to 31 Dec 2018.
- 19 Mar 2018 Planned End Date changed from 30 Jun 2021 to 30 Nov 2019.